0000950170-24-069439.txt : 20240605 0000950170-24-069439.hdr.sgml : 20240605 20240605173044 ACCESSION NUMBER: 0000950170-24-069439 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 241023128 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: PIMSTONE SIMON N. CENTRAL INDEX KEY: 0001620084 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G4W8 144 1 primary_doc.xml 144 0001620084 XXXXXXXX LIVE 0001582313 Xenon Pharmaceuticals Inc. 001-36687 200-3650 Gilmore Way Burnaby A1 V5G 4W8 (604)-484-3300 SIMON PIMSTONE Former Director Common Shares Morgan Stanley Wealth Management Canada Inc.

Suite 1500, 600 - 3 Avenue SW Calgary Z4 T2P 0G5

110000 4197600 75468883 06/05/2024 NASDAQ Stock Option 12/18/2015 Equity Incentive Grant Issuer N 30682 06/05/2024 See remarks Stock Option 03/11/2016 Equity Incentive Grant Issuer N 50000 06/05/2024 See remarks Stock Option 03/13/2017 Equity Incentive Grant Issuer N 140000 06/05/2024 See remarks Stock Option 10/23/2017 Equity Incentive Grant Issuer N 11000 06/05/2024 See remarks Stock Option 03/12/2018 Equity Incentive Grant Issuer N 140000 06/05/2024 See remarks Stock Option 09/16/2019 Equity Incentive Grant Issuer N 95000 06/05/2024 See remarks Y The reporting person anticipates selling up to 110,000 common shares during the 90-day period following the filing of this Form 144 to cover tax obligations arising from the net exercise of the listed stock options. 06/05/2024 /s/ Simon Pimstone